Abstract:161Tb is an interesting radionuclide for application in the treatment of neuroendocrine neoplasms' small metastases and single cancer cells because of its conversion and Auger-electron emission. Tb has coordination chemistry similar to that of Lu; therefore, like 177Lu, it can stably radiolabel DOTATOC, one of the leading peptides used for the treatment of neuroendocrine neoplasms. However, 161Tb is a recently developed radionuclide that has not yet been specified for clinical use. Therefore, the aim of the current work was to characterize and specify 161Tb and to develop a protocol for the synthesis and quality control of 161Tb-DOTATOC with a fully automated process conforming to good-manufacturing-practice guidelines, in view of its clinical use. Methods: 161Tb, produced by neutron irradiation of 160Gd in high-flux reactors followed by radiochemical separation from its target material, was characterized regarding its radionuclidic purity, chemical purity, endotoxin level, and radiochemical purity (RCP) in analogy to what is described in the European Pharmacopoeia for no-carrier-added 177Lu. In addition, 161Tb was introduced into a fully automated cassette-module synthesis to produce 161Tb-DOTATOC, as used for 177Lu-DOTATOC. The quality and stability of the produced radiopharmaceutical in terms of identity, RCP, and ethanol and endotoxin content were assessed by means of high-performance liquid chromatography, gas chromatography, and an endotoxin test, respectively. Results: 161Tb produced under the described conditions showed, as the no-carrier-added 177Lu, a pH of 1-2, radionuclidic purity and RCP of more than 99.9%, and an endotoxin level below the permitted range (175 IU/mL), indicating its appropriate quality for clinical use. In addition, an efficient and robust procedure for the automated production and quality control of 161Tb-DOTATOC with clinically applicable specifications and activity levels, that is, 1.0-7.4 GBq in 20 mL, was developed. The radiopharmaceutical's quality control was also developed using chromatographic methods, which confirmed the product's stability (RCP ≥ 95%) over 24 h. Conclusion: The current study demonstrated that 161Tb has appropriate features for clinical use. The developed synthesis protocol guarantees high yields and safe preparation of injectable 161Tb-DOTATOC. The investigated approach could be translated to other DOTA-derivatized peptides; thus, 161Tb could be successfully applied in clinical practice for radionuclide therapy.

Production of pharmaceutical grade [201Tl]Thallous chloride using 30 MeV cyclotron

Study of thulium-167 cyclotron production: a potential medically-relevant radionuclide

Production of copper-64 and gallium-68 with a medical cyclotron using liquid targets

Production and separation of 99mTc from cyclotron irradiated 100/naturalMo targets: a new automated module for separation of 99mTc from molybdenum targets

The Cyclotron Production of Actinium-225 in CYCIAE-100

Production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair

Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets

Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target

Production and Isolation of Actinium-225 for Targeted Radiotherapy with a 100 MeV Proton Cyclotron and Solid-Phase Extraction

Design study of an ultra-compact superconducting cyclotron for isotope production

Production, purification and formulation of nanoradiopharmaceutical with 211At: An emerging candidate for targeted alpha therapy

The production and separation of 161Tb with high specific activity at the University of Utah

155Tb production by cyclotrons: what level of 155Gd enrichment allows clinical applications?

Hybridised production of technetium-99m and technetium-101 with fluorine-18 on a low-energy biomedical cyclotron

Production and radiochemical separation of 68 Ge from irradiated Ga–Ni alloy target in 30 MeV cyclotron

Practical experience and challenges in the operation of medical cyclotron

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy

Production of 225 Ac for medical application from 232 Th-metallic targets in Nb-shells irradiated with middle-energy protons

Production of 76Br by a low-energy cyclotron

Optimization of 18F Radioisotope Production with Cyclone 18/9 MeV IBA Cyclotron Installed at NINMAS

161Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of 161Tb into the Clinic